Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 3 with minor changes only.

1. Minor

   3 trials marked Unknown by the registry's verification sweep

   1. Minor

      Relative Bioavailability and Food Effect Study of HDM1002 in…Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects

      Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting

      Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1· NCT06608329· Registry history of NCT06608329 on ClinicalTrials.gov (opens the registry)

      Changed Oct 4, 2026

   2. Minor

      Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide…Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects

      Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting

      Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1· NCT06601517· Registry history of NCT06601517 on ClinicalTrials.gov (opens the registry)

      Changed Oct 4, 2026

   3. Minor

      Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects

      Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

      Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1· NCT06576401· Registry history of NCT06576401 on ClinicalTrials.gov (opens the registry)

      Changed Oct 4, 2026

   Registry verification sweep

   Changed Oct 4, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.